Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nalbuphine HCl ER Extension in Uremic Pruritus
NCT02143973Phase 3Completed
- Sponsor
- Trevi Therapeutics
- Start
- Sep 2014
- Primary completion
- Jan 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nalbuphine in uremic pruritus, sponsored by Trevi Therapeutics. Primary endpoint: Treatment Emergent Adverse Events at 24 weeks. Started Sep 2014; status: completed.
02
Drugs
nalbuphine
03
Conditions
uremic pruritus
Beyond the preview
Go deeper on NCT02143973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02143973.